Rejection of a Nonimmunogenic Melanoma by Vaccination with Natural Melanoma Peptides on Engineered Antigen-Presenting Cells

Journal of Immunology

Volumn 158, Issue 2, 1997, Pages 783-789

  Bellone, Matteo ^a,c   Iezzi, Giandomenica ^a   Martin Fontecha, Alfonso ^a   Rivolta, Loredana ^a   Manfredi, Angelo A ^a   Protti, Maria Pia ^a   Freschi, Massimo ^a   Dellabona, Paolo ^a   Casorati, Giulia ^a   Rugarli, Claudio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; RECOMBINANT VACCINE; TUMOR ANTIGEN;

ANIMAL; ANTIGEN PRESENTING CELL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; FEMALE; GRAFT REJECTION; IMMUNOLOGY; METABOLISM; MOUSE; NATURAL KILLER CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; GRAFT REJECTION; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC;

EID: 0031567983     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Hellstrom, K. E., and I. Hellstrom. 1991. Principles of tumor immunity: tumor antigens. In The Biologic Therapy of Cancer. V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, eds. J. B. Lippincott Co., Philadelphia, p. 35.
2. Melief, C. J. M. 1992. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58:143.
3. Parmiani, G., A. Anichini, and G. Fossati. 1990. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J. Natl. Cancer Inst. 82:361.
4. Boon, T., J. C. Cerottini, B. Van den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
5. Slingluff, C. L., D. F. Hunt, and V. H. Engelhard. 1994. Direct analysis of tumorassociated peptide antigens. Curr. Opin. Immunol. 6:733.
6. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
7. Mueller, D. L., M. K. Jenkins, R. H. and Schwartz. 1989. Clonal expansion vs. functional clonal inactivation: a costimulatory pathway determines the outcome of T cell receptor occupancy. Annu. Rev. Immunol. 7:445.
8. Liu, Y., and P. S. Linsley. 1992. Costimulation of T cell growth. Curr. Opin. Immunol. 4:265.
9. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
10. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
11. Talmage, D. W., J. A. Woolnough, H. Hemmingsen, L. Lopez, and K. J. Laferty. 1977. Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s). Proc. Natl. Acad. Sci. USA 74:4610.
12. Chen, L., P. S. Linsley, and K. E. Hellstrom. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
13. Hellstrom, K. E., I. Hellstrom, and L. Chen. 1995. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145:122.
14. Cavallo, F., A. Martin-Fontecha, M. Bellone, S. Heltai, E. Gatti, P. Tornaghi, M. Freschi, G. Forni, P. Dellabona, and G. Casorati. 1995. Co-expression of B7.1 and ICAM-1 on tumors is required for rejection and establishment of a memory response. Eur. J. Immunol. 25:1154.
15. Grabbe, S., S. Beissert, T. Schwarz, and R. D. Granstein. 1995. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16:117.
16. Young, J. W., and K. Inaba. 1996. Dendritic cells as adjuvants for class I majoir histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:7.
17. Williams, N. 1996. An immune boost to the war on cancer. Science 272:28.
18. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celuzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297.
19. Hsu F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
20. Tanaka, Y., and S. S. Tevethia. 1988. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocytes clones. J. Immunol. 140: 4348.
21. Storkus, W. J., H. J. Zeh III, M. J. Maeuer, R. D. Salter, and M. Lotze. 1993. Identification of human melanoma peptides recognized by class I-restricted tumor-infiltrating lymphocytes. J. Immunol. 151:3719.
22. + cytotoxic T lymphocytes. J. Exp. Med. 181:363.
23. Rotzschke, O., and K. Falk. 1991. Naturally occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol. Today 12:447.
24. Mandelboim, O., G. Berke, M. Fridkin, M. Feldman, M. Eisenstein, and L. Eisenbach. 1994. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67.
25. Franksson, L., M. Petersson, R. Kiessling, and K. Karre. 1993. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur. J. Immunol. 23:2606.
26. Ljunggren, H.-G., and K. Karre. 1985. Host resistance directed selectively against H-2-deficient lyraphoma variants. J. Exp. Med. 162:1745.
27. Yang, Y, K. Fruhe, J. Chambers, J. B. Waters, L. Wu, T. Spies, and P. A. Peterson. 1992. Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class-I MHC molecules. J. Biol. Chem. 267:11669.
28. De Bruijn, M. L. H., T. N. M. Schumacher, J. D. Nieland, H. L. Ploegh, W. M. Kast, and C. J. M. Melief. 1991. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte response. Eur. J. Immunol. 21:2963.
29. Schumacher, T. N. M., M.-T. Heemels, J. J. Neefjes, W. M. Kast, C. J. M. Melief, and H. L. Ploegh. 1990. Direct binding of peptide to empty MHC class I molecule on intact cells and in vitro. Cell 62:563.
30. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
31. Bellone, M., G. Iezzi, A. A. Manfredi, M. P. Protti, P. Dellabona, G. Casorati, and C. Rugarli. 1994. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur. J. Immunol. 24:2691.
32. Bellone, M., N. Ostlie, S. Lei, and B. M. Conti-Tronconi. 1991. Experimental myasthenia gravis in congenic mice: sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol. 21:2303.
33. Greene, E. L., ed. Handbook on Genetically Standardized Jak Mice. 1986. McGraw Hill, New York.
34. Celik, C. D., D. A. Lewis, and M. H. Goldrosen. 1983. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma. Cancer Res. 43: 3507.
35. Tanaka, K., E. Groelik, M. Watanabe, N. Hozumi, and G. Jay. 1988. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol. Cell Biol. 8:1857.
36. Bevan, M. 1995. Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med. 182:639.
37. + tumor-infiltrating lymphocytes. J. Immunol. 153:1202.
38. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immuity. Proc. Natl. Acad. Sci. USA 90:3539.
39. Stobo, J. D. 1987. Lymphocytes. In Basic and Clinical Immunology. D. P. Stites, J. D. Stobo, and J. V. Wells, eds. Appleton and Lange, Norwalk, CA, p. 65.
40. Huang, A. Y. C., P. Golumbeck, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC I-restricted tumor antigens. Science 264:961.
41. Huang, A. Y. C., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
42. Kunding, T. M., M. F. Bachmann, C. DiPaolo, J. J. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343.
43. Mackay, C. R., W. L. Marston, and L. Dudler. 1990. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. 171:801.
44. Barber, L. D., and P. Parham. 1993. Peptide binding to major histocompatibility complex molecules. Annu. Rev. Cell Biol. 9:163.
45. Chicz, R. M., R. G. Urban, J. C. Gorga, D. A. A. Vignali, W. S. Lane, and J. L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27.
46. Steinman, R. M., and J. Swanso. 1995. The endocytic activity of dendritic cells. J. Exp. Med. 182:283.
47. Townsend, S. E., W. S. Fannie, J. M. Atherton, and J. P. Allison. 1994. Specificity and longevity of antitumor immune response induced by B7-transfected tumors. Cancer Res. 54:6477.
48. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991.
49. Moudgil, K. D., and E. E. Sercarz. 1994. Can the antigen-tumor immune response discriminate between self and non-self? Immunol. Today 15:353.
50. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th1-associated cytokines. J. Exp. Med. 183:87.
51. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109.
52. Protti, M. P., M. A. Imro, A. A. Manfredi, G. Consogno, S. Heltai, C. Arcelloni, M. Bellone, P. Dellabona, G. Casorati, and C. Rugarli. 1996. Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro. Cancer Res. 56:1210.